Exanta - Oral Direct Thrombin Inhibitor for the Prevention and Treatment of Venous Thromboembolism
Exanta (ximelagatran) is an oral direct thrombin inhibitor developed by AstraZeneca. It is indicated for the prevention and treatment of venous thromboembolism (VTE) and potentially for the prevention of stroke in patients with atrial fibrillation. (Source: ABPI)
